Europe Intrauterine Contraceptive Device Market Forecast 2017-2025
KEY FINDINGS The Europe intrauterine device market is predicted to reach $1033 million by the end of 2025, rising from $780 million in 2016. This growth can be attributed to the estimated rise in the market’s CAGR by 3.24% over the forecast period of 2017-2025.
MARKET INSIGHTS According to the Guttmacher Institute, IUCD is an essential part of family planning in the European countries. As per the statics, these devices account for nearly 9%-24% of all contraceptive methods in Europe. The major contributor to the European market is the United Kingdom. The effectiveness of the IUCDs over other devices has increased their popularity among females who are in their twenties. However, the risk of instigating pelvic inflammatory infection (PID) or of an ectopic pregnancy is challenging the market growth.
COMPETITIVE INSIGHTS Trimedic Supply Network Ltd, Mona Lisa N.V, Bayers Ag, Melbea, Merck & Co, Medisafe Distribution Inc, Pfizer, DKT International, Allergan Plc, HLL Lifecare Limited, Teva Pharmaceutical Industries Limited, Pregna, and Meril Life Sciences Private Limited are few of the established companies in the market.